Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Chronic heart failure patient and COVID-19: Focus on laboratory markers of myocardial damage
https://doi.org/10.33667/2078-5631-2023-23-19-22
Abstract
The aim of the study. To determine the severity of the current COVID-19 in patients with CHF.
Materials and methods. The study included data from 98 patients diagnosed with COVID-19 in combination with CHF. The data on the duration of hospitalization, the severity of the lesion, the dynamics of the level of laboratory parameters are analyzed.
Results. In 68 patients with CHF 2A, stage I of CHF in 27 patients and in 3 patients – stage 0. CHF of functional class I – 23 patients, FC II – 73 patients, FC III – 2 patients. The average duration of hospitalization was 15 days. Blood saturation (SpO2) in the range of 95–100 % was determined in 75 patients, 90–95 % – in 20 people, less than 90 % – in 3 patients. In 42.86 % of patients, an increase in the level of D-dimer was detected according to laboratory studies.
Conclusions. Patients 60 years and older with CHF 2A and FC II with pronounced clinical symptoms are at risk of severe infection requiring hospitalization. Concomitant diseases of the cardiovascular system increase the duration of hospitalization.
About the Authors
N. V. Bagisheva
Omsk State Medical University
Russian Federation
Russian Federation
Natalia V. Bagisheva, PhD Med, associate professor
Dept of Polyclinic Therapy and Internal Diseases
Omsk
M. V. Moiseeva
Omsk State Medical University
Russian Federation
Russian Federation
Marina V. Moiseeva, PhD Med, associate professor
Dept of Polyclinic Therapy and Internal Diseases
Omsk
A. V. Mordyk
Omsk State Medical University; National Medical Research Centre for Phthisiopulmonology and Infectious Diseases
Russian Federation
Russian Federation
Anna V. Mordyk, D. Sci. (Med.), professor, head of Dept
Dept of Phthisiology, Pulmonology and Infectious Diseases
Omsk
Moscow
V. V. Streltsova
Omsk State Medical University
Russian Federation
Russian Federation
Victoria V. Streltsova, 6th year student
Faculty of Medicine
Omsk
E. P. Antipova
Omsk State Medical University
Russian Federation
Russian Federation
Ekaterina P. Antipova, assistant
Omsk
References
1. Li B Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020; 109 (5): 531–538. DOI: 10.1007/s00392–020–01626–9
2. Xiong T. Y., Redwood S., Prendergast B., et al. Coronaviruses and the cardiovascular system: Acute and long-term implications. Eur Heart J. 2020; 41 (19): 1798–1800. DOI: 10.1093/eurheartj/ehaa231
3. Zhou F., Yu T., Du R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study [published correction appears in Lancet]. 2020. DOI: 10.1016/S0140–6736(20)30566–3
4. Huang C Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet]. 2020 Jan 30, 2020; 395 (10223): 497–506. DOI: 10.1016/s0140–6736(20)30183–5
5. Chen D., Li X., Song Q., et al. Hypokalemia and Clinical Implications in Patients with Coronavirus Disease 2019 (COVID-19) medRxiv 2020; DOI: 10.1101/2020.02.27.20028530
6. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020; 14 (3): 247–250. DOI: 10.1016/j.dsx.2020.03.013
7. Huang C. Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020 Jan 30, 2020; 395 (10223): 497–506. DOI: 10.1016/s0140–6736(20)30183–5
8. Brunner-La Rocca H. P., Sanders-van Wijk S. Natriuretic Peptides in Chronic Heart Failure. Card Fail Rev. 2019; 5 (1): 44–49. DOI: 10.15420/cfr.2018.26.1
9. Danesh J., Kaptoge S., Mann A. G. et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: Two new prospective studies and a systematic review. PLoS Med 2008; 5 (4): 78. DOI: 10.1371/journal.pmed.0050078
10. Tehrani D. M., Gardin J. M., Yanez D. et al. Impact of inflammatory biomarkers on relation of high-density lipoprotein cholesterol with incident coronary heart disease: Cardiovascular Health Study. Atherosclerosis 2013; 231 (2): 246–51. DOI: 10.1016/j.atherosclerosis.2013.08.036
11. Kaptoge S., Seshasai S.1R.K., Gao P. et al. Inflammatory cytokines and risk of coronary heart disease: New prospective study and updated meta-analysis. Eur Heart J 2014; 35 (9): 578–89. DOI: 10.1093/eurheartj/eht367
12. Arutiunov G. P., Tarlovskaia E. I., Koziolova N. A., et al. The agreed experts’ position of the Eurasian Association of Therapists on tactics of management of patients with comorbid pathology infected with SARS-Cov-2. Therapeutic Archive. 2020; 92 (9): 108–124 (In Russ.). DOI: 10.26442/00403660.2020.09.000703
13. Tsvetkov V. V., Tokin I. I., Lioznov D. A., Venev E. V., Kulikov A. N. Predicting the duration of inpatient treatment for COVID-19 patients. Medical Council. 2020; (17): 82–90 (In Russ.). DOI: 10.21518/2079–701x-2020–17–82–90
Review
For citations:
Bagisheva N.V., Moiseeva M.V., Mordyk A.V., Streltsova V.V., Antipova E.P. Chronic heart failure patient and COVID-19: Focus on laboratory markers of myocardial damage. Modern Laboratory (2). 2023;(23):19-22. (In Russ.) https://doi.org/10.33667/2078-5631-2023-23-19-22
Views:
237
Email this article 